FR23C1012I1 - ANTI-BCMA ANTIBODIES, BCMA AND CD3-BINDING BISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - Google Patents
ANTI-BCMA ANTIBODIES, BCMA AND CD3-BINDING BISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOFInfo
- Publication number
- FR23C1012I1 FR23C1012I1 FR23C1012C FR23C1012C FR23C1012I1 FR 23C1012 I1 FR23C1012 I1 FR 23C1012I1 FR 23C1012 C FR23C1012 C FR 23C1012C FR 23C1012 C FR23C1012 C FR 23C1012C FR 23C1012 I1 FR23C1012 I1 FR 23C1012I1
- Authority
- FR
- France
- Prior art keywords
- bcma
- binding
- bispecific antigen
- antibodies
- binding molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562206246P | 2015-08-17 | 2015-08-17 | |
PCT/US2016/047146 WO2017031104A1 (en) | 2015-08-17 | 2016-08-16 | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
FR23C1012I1 true FR23C1012I1 (en) | 2023-04-14 |
Family
ID=56740579
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR23C1011C Active FR23C1011I1 (en) | 2015-08-17 | 2023-02-22 | ANTI-BCMA ANTIBODIES, BCMA AND CD3-BINDING BISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF |
FR23C1012C Active FR23C1012I1 (en) | 2015-08-17 | 2023-02-22 | ANTI-BCMA ANTIBODIES, BCMA AND CD3-BINDING BISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR23C1011C Active FR23C1011I1 (en) | 2015-08-17 | 2023-02-22 | ANTI-BCMA ANTIBODIES, BCMA AND CD3-BINDING BISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF |
Country Status (40)
Country | Link |
---|---|
US (1) | US10072088B2 (en) |
EP (2) | EP3337824B1 (en) |
JP (3) | JP2018525005A (en) |
KR (1) | KR20180040671A (en) |
CN (1) | CN108350076B (en) |
AR (1) | AR105724A1 (en) |
AU (1) | AU2016308567B2 (en) |
BR (1) | BR112018003017A2 (en) |
CA (1) | CA2995754A1 (en) |
CL (1) | CL2018000431A1 (en) |
CO (1) | CO2018001524A2 (en) |
CY (2) | CY1123297T1 (en) |
DK (1) | DK3337824T3 (en) |
EA (1) | EA201890513A1 (en) |
EC (1) | ECSP18019568A (en) |
ES (1) | ES2814550T3 (en) |
FI (1) | FIC20230012I1 (en) |
FR (2) | FR23C1011I1 (en) |
HR (1) | HRP20201375T1 (en) |
HU (2) | HUE050556T2 (en) |
IL (2) | IL298041A (en) |
JO (1) | JO3799B1 (en) |
LT (2) | LT3337824T (en) |
MA (1) | MA53750A (en) |
MX (2) | MX2018002043A (en) |
MY (1) | MY191325A (en) |
NI (1) | NI201800027A (en) |
NL (1) | NL301219I2 (en) |
PE (1) | PE20180795A1 (en) |
PH (1) | PH12018500361A1 (en) |
PL (1) | PL3337824T3 (en) |
PT (1) | PT3337824T (en) |
RS (1) | RS60755B1 (en) |
SI (1) | SI3337824T1 (en) |
SV (1) | SV2018005634A (en) |
TW (3) | TWI811023B (en) |
UA (1) | UA127515C2 (en) |
UY (1) | UY36859A (en) |
WO (1) | WO2017031104A1 (en) |
ZA (1) | ZA201801789B (en) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
KR101997241B1 (en) | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | Trispecific binding proteins and methods of use |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
WO2017123741A1 (en) | 2016-01-12 | 2017-07-20 | Institute For Myeloma & Bone Cancer Research | Improved methods for monitoring immune status of a subject |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
MA44254A (en) | 2016-02-17 | 2018-12-26 | Seattle Genetics Inc | BCMA ANTIBODIES AND THEIR USE TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS |
EA039084B1 (en) * | 2016-05-09 | 2021-12-01 | Бристол-Майерс Сквибб Компани | Tl1a antibodies and uses thereof |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | Single domain serum albumin binding protein |
TWI781108B (en) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof |
BR122022002481A8 (en) | 2016-09-14 | 2023-02-07 | Teneobio Inc | BISPECIFIC BINDING ANTIBODIES SPECIFIC TO CD3DELTA-EPSILON |
JP7254699B2 (en) | 2016-12-21 | 2023-04-10 | テネオバイオ, インコーポレイテッド | Anti-BCMA heavy chain only antibody |
CN110582509A (en) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | Treatment of cancer using chimeric T cell receptor proteins with multispecific properties |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
CN113896792A (en) | 2017-05-12 | 2022-01-07 | 哈普恩治疗公司 | Mesothelin binding proteins |
US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
EP3642236A1 (en) | 2017-06-20 | 2020-04-29 | TeneoOne, Inc. | Anti-bcma heavy chain-only antibodies |
AU2018289515A1 (en) | 2017-06-20 | 2020-02-06 | Teneobio, Inc. | Anti-BCMA heavy chain-only antibodies |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | Chimeric antibody immune effctor cell engagers and methods of use thereof |
CA3070539A1 (en) * | 2017-08-01 | 2019-02-07 | Medimmune, Llc | Bcma monoclonal antibody-drug conjugate |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
WO2019046818A1 (en) * | 2017-09-01 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Immunogenic peptides specific to bcma and taci antigens for treatment of cancer |
KR102464826B1 (en) | 2017-10-13 | 2022-11-08 | 하푼 테라퓨틱스, 인크. | Trispecific proteins and methods of use |
CR20200195A (en) | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | B cell maturation antigen binding proteins |
JP2021501570A (en) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | Compositions and Methods for Selective Proteolysis |
US11623961B2 (en) * | 2017-11-01 | 2023-04-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for B-cell maturation antigen |
MX2020004948A (en) | 2017-11-15 | 2020-11-11 | Novartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies. |
MX2020005651A (en) | 2017-11-30 | 2020-10-28 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof. |
CN112218651A (en) | 2018-01-08 | 2021-01-12 | 诺华公司 | Immunopotentiating RNA for combination with chimeric antigen receptor therapy |
EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
EP3774901A1 (en) * | 2018-03-26 | 2021-02-17 | Sutro Biopharma, Inc. | Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies |
BR112020020828A2 (en) * | 2018-04-13 | 2021-01-19 | Affimed Gmbh | BINDING PROTEINS, PHARMACEUTICAL COMPOSITIONS, METHOD FOR TREATMENT OR IMPROVEMENT OF A DISEASE, TO TREAT AND/OR PREVENT A DISEASE, TO TREAT A PATIENT AND TO TREAT CANCER AND ANTIBODIES |
MA52640A (en) * | 2018-05-16 | 2021-03-24 | Janssen Biotech Inc | METHODS FOR TREATING CANCERS AND IMPROVING THE EFFECTIVENESS OF THERAPEUTIC T-LYMPHOCYTE REDIRECTION AGENTS |
WO2019229701A2 (en) * | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
CN112203725A (en) | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | BCMA chimeric antigen receptors and uses thereof |
KR20210020900A (en) * | 2018-06-14 | 2021-02-24 | 블루버드 바이오, 인코포레이티드. | Anti-BCMA CAR antibodies, conjugates and methods of use |
KR102597053B1 (en) * | 2018-06-26 | 2023-11-02 | 에이비엘바이오 주식회사 | Anti-BCMA antibodies and their uses |
AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
TWI838389B (en) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | BISPECIFIC ANTI-BCMAxANTI-CD3 ANTIBODIES AND USES THEREOF |
MX2021001083A (en) * | 2018-07-31 | 2021-03-31 | Amgen Res Munich Gmbh | Dosing regimen for bcma-cd3 bispecific antibodies. |
PE20211860A1 (en) * | 2018-08-08 | 2021-09-21 | Dragonfly Therapeutics Inc | MULTI-SPECIFIC BINDING PROTEINS BINDING BCMA, NKG2D AND CD16 AND METHODS OF USE |
CN112639083A (en) | 2018-08-31 | 2021-04-09 | 诺华股份有限公司 | Method for producing cells expressing chimeric antigen receptor |
US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
KR20210086623A (en) | 2018-09-25 | 2021-07-08 | 하푼 테라퓨틱스, 인크. | DDL3 Binding Proteins and Methods of Use |
JP7410143B2 (en) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | Bispecific antibodies and their uses |
US20220056132A1 (en) * | 2018-12-19 | 2022-02-24 | City Of Hope | Baff-r bispecific t-cell engager antibody |
CA3128034A1 (en) * | 2019-02-01 | 2020-08-06 | Glaxosmithkline Intellectual Property Development Limited | Belantamab mafodotin in combination with pembrolizumab for treating cancer |
JP2022523204A (en) | 2019-02-25 | 2022-04-21 | ノバルティス アーゲー | Mesoporous silica particle composition for virus delivery |
SG11202109163YA (en) * | 2019-02-26 | 2021-09-29 | Sorrento Therapeutics Inc | Antigen binding proteins that bind bcma |
EP3941589A1 (en) | 2019-03-21 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
EP3733707A1 (en) | 2019-04-30 | 2020-11-04 | Celyad S.A. | Car t-cells targeting bcma and uses thereof |
BR112021021728A2 (en) * | 2019-05-03 | 2021-12-28 | Celgene Corp | Anti-bcma antibody conjugate, compositions comprising the same, and methods for making and using the same |
JOP20210323A1 (en) | 2019-06-14 | 2023-01-30 | Teneobio Inc | Multispecific heavy chain antibodies binding to cd22 and cd3 |
CN110229232B (en) * | 2019-06-19 | 2020-05-19 | 北京智仁美博生物科技有限公司 | Bispecific antibodies and uses thereof |
CN112585168B (en) * | 2019-07-30 | 2022-04-15 | 上海翰森生物医药科技有限公司 | anti-BCMA antibodies, antigen binding fragments thereof, and medical uses thereof |
WO2021092060A1 (en) * | 2019-11-05 | 2021-05-14 | Engmab Sarl | Methods of treatment |
IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
CN114929343A (en) * | 2019-12-06 | 2022-08-19 | 瑞泽恩制药公司 | Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD 3 antibodies |
WO2021132746A1 (en) * | 2019-12-24 | 2021-07-01 | Abl Bio, Inc. | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
AU2020400801A1 (en) * | 2019-12-10 | 2022-07-07 | Abl Bio, Inc. | Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof |
WO2021127007A1 (en) * | 2019-12-16 | 2021-06-24 | Bluebird Bio, Inc. | Anti-bcma car antibodies, conjugates, and methods of use |
EP4110376A2 (en) | 2020-02-27 | 2023-01-04 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
MX2022010685A (en) | 2020-02-27 | 2022-09-23 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells. |
US20210284730A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Materials and methods for modulating delta chain mediated immunity |
TW202144425A (en) * | 2020-04-17 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | Specific antigen binding molecule, preparation method and pharmaceutical use thereof |
CR20230149A (en) | 2020-04-29 | 2023-05-25 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
TW202330622A (en) * | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | Multispecific heavy chain antibodies with modified heavy chain constant regions |
CN113637073B (en) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | BCMA antibody, preparation and application thereof |
CA3182697A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
WO2021234560A1 (en) | 2020-05-19 | 2021-11-25 | Janssen Biotech, Inc. | Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor |
WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
MX2022016342A (en) | 2020-06-30 | 2023-01-24 | Teneobio Inc | Multi-specific antibodies binding to bcma. |
CN114075287B (en) * | 2020-08-18 | 2023-07-21 | 湖南远泰生物技术有限公司 | Humanized BCMA antibodies and BCMA-CAR-T cells |
EP4199960A2 (en) | 2020-08-21 | 2023-06-28 | Novartis AG | Compositions and methods for in vivo generation of car expressing cells |
CA3194771A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
WO2022098771A1 (en) * | 2020-11-03 | 2022-05-12 | Ab Studio Inc. | Multispecific antibodies and uses thereof |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
WO2022135468A1 (en) * | 2020-12-23 | 2022-06-30 | 信达生物制药(苏州)有限公司 | Anti-bcma×cd3 bispecific antibody and use thereof |
WO2022165171A1 (en) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
CR20230398A (en) | 2021-02-16 | 2023-11-15 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
EP4301785A1 (en) * | 2021-03-05 | 2024-01-10 | Atreca, Inc. | Epha2 antibodies |
BR112023019484A2 (en) | 2021-03-24 | 2023-12-05 | Janssen Biotech Inc | TRIESPECIFIC ANTIBODY THAT TARGETS CD79B, CD20 AND CD3 |
KR20240004462A (en) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Multifunctional molecules that bind to TCR and their uses |
WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
EP4329818A1 (en) | 2021-04-30 | 2024-03-06 | Celgene Corporation | Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi) |
TW202309522A (en) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma |
EP4347039A1 (en) | 2021-05-28 | 2024-04-10 | Janssen Biotech, Inc. | Bcma as a target for t cell redirecting antibodies in b cell lymphomas |
CN115521381A (en) * | 2021-06-24 | 2022-12-27 | 益科思特(北京)医药科技发展有限公司 | Bispecific antibody combining BCMA and CD3, preparation method and application thereof |
CN115569191A (en) * | 2021-07-05 | 2023-01-06 | 山东新时代药业有限公司 | Recombinant humanized anti-BCMA/CD 3 bispecific antibody freeze-dried preparation |
WO2023020474A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Bcma targetting antibodies and uses thereof in cancer therapies |
CA3229746A1 (en) | 2021-08-20 | 2023-02-23 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP4416292A2 (en) | 2021-10-14 | 2024-08-21 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
WO2023076921A1 (en) * | 2021-10-27 | 2023-05-04 | Janssen Biotech, Inc. | Methods for enhanced bcma immunohistochemistry detection in human and monkey tissue |
MX2024005406A (en) | 2021-11-03 | 2024-08-06 | Janssen Biotech Inc | Corticosteriod reduction in treatment with anti-cd38 antibodies. |
IL312503A (en) | 2021-11-03 | 2024-07-01 | Janssen Biotech Inc | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies |
TW202328209A (en) * | 2021-11-10 | 2023-07-16 | 美商健生生物科技公司 | Stable formulations comprising a bispecific bcma/cd3 antibody |
CN118696058A (en) * | 2021-12-03 | 2024-09-24 | 山东先声生物制药有限公司 | Anti-BCMA nano antibody and application thereof |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
CN117003871A (en) | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | Antibodies that bind BCMA and CD3 and uses thereof |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
WO2024095173A1 (en) | 2022-11-02 | 2024-05-10 | Janssen Biotech, Inc. | Methods of treating cancers |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
WO2024119126A1 (en) * | 2022-12-02 | 2024-06-06 | Artiva Biotherapeutics, Inc. | Anti-bcma antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
CN117186228B (en) * | 2022-12-06 | 2024-03-22 | 成都赛恩吉诺生物科技有限公司 | Bispecific antibody of anti-human BCMA nano antibody containing long CDR3 sequence and application |
WO2024124088A1 (en) * | 2022-12-09 | 2024-06-13 | Sana Biotechnology, Inc. | Bcma-specific antibody constructs and compositions thereof |
WO2024173830A2 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1015576T3 (en) | 1997-09-16 | 2005-08-29 | Egea Biosciences Llc | Method for complete chemical synthesis and aggregation of genes and genomes |
US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
UA74798C2 (en) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors |
WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
CA2438682A1 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
DE102005028778A1 (en) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food |
ES2856451T3 (en) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Compositions comprising specific antibodies for different species, and uses thereof |
US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
AU2008234019B2 (en) | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
RS58217B1 (en) | 2007-04-03 | 2019-03-29 | Amgen Res Munich Gmbh | Cross-species-specific binding domain |
WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
EP2352763B2 (en) | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
WO2010037838A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
PT2356153T (en) | 2008-10-01 | 2016-07-15 | Amgen Res (Munich) Gmbh | Cross-species-specific psmaxcd3 bispecific single chain antibody |
EA028304B1 (en) | 2008-10-31 | 2017-11-30 | Сентокор Орто Байотек Инк. | Methods of constructing a library of a protein scaffold based on a fibronectin type iii (fn3) domain |
WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
PT2406284T (en) | 2009-03-10 | 2016-09-29 | Biogen Ma Inc | Anti-bcma antibodies |
US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
MX353144B (en) | 2010-04-20 | 2017-12-20 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof. |
PT2635607T (en) | 2010-11-05 | 2019-12-11 | Zymeworks Inc | Stable heterodimeric antibody design with mutations in the fc domain |
EP2640750A1 (en) * | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
EP2710042A2 (en) * | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
CN104114186B (en) * | 2011-08-03 | 2017-05-03 | 儿童医疗中心有限公司 | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
PT2773671T (en) | 2011-11-04 | 2021-12-14 | Zymeworks Inc | Stable heterodimeric antibody design with mutations in the fc domain |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
PL2931030T5 (en) | 2012-12-14 | 2024-06-10 | Open Monoclonal Technology, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
EP2762497A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
-
2016
- 2016-08-16 SI SI201630895T patent/SI3337824T1/en unknown
- 2016-08-16 EP EP16754148.1A patent/EP3337824B1/en active Active
- 2016-08-16 TW TW111126438A patent/TWI811023B/en active
- 2016-08-16 JO JOP/2016/0184A patent/JO3799B1/en active
- 2016-08-16 EP EP20177664.8A patent/EP3757131A1/en active Pending
- 2016-08-16 CA CA2995754A patent/CA2995754A1/en active Pending
- 2016-08-16 TW TW105126031A patent/TWI777924B/en active
- 2016-08-16 ES ES16754148T patent/ES2814550T3/en active Active
- 2016-08-16 HU HUE16754148A patent/HUE050556T2/en unknown
- 2016-08-16 US US15/237,889 patent/US10072088B2/en active Active
- 2016-08-16 BR BR112018003017-1A patent/BR112018003017A2/en active Search and Examination
- 2016-08-16 WO PCT/US2016/047146 patent/WO2017031104A1/en active Application Filing
- 2016-08-16 IL IL298041A patent/IL298041A/en unknown
- 2016-08-16 JP JP2018508695A patent/JP2018525005A/en active Pending
- 2016-08-16 MA MA053750A patent/MA53750A/en unknown
- 2016-08-16 PL PL16754148T patent/PL3337824T3/en unknown
- 2016-08-16 LT LTEP16754148.1T patent/LT3337824T/en unknown
- 2016-08-16 MY MYPI2018700579A patent/MY191325A/en unknown
- 2016-08-16 AU AU2016308567A patent/AU2016308567B2/en active Active
- 2016-08-16 CN CN201680060812.2A patent/CN108350076B/en active Active
- 2016-08-16 UA UAA201802674A patent/UA127515C2/en unknown
- 2016-08-16 TW TW112124028A patent/TW202406935A/en unknown
- 2016-08-16 PE PE2018000262A patent/PE20180795A1/en unknown
- 2016-08-16 KR KR1020187007297A patent/KR20180040671A/en not_active Application Discontinuation
- 2016-08-16 DK DK16754148.1T patent/DK3337824T3/en active
- 2016-08-16 PT PT167541481T patent/PT3337824T/en unknown
- 2016-08-16 EA EA201890513A patent/EA201890513A1/en unknown
- 2016-08-16 MX MX2018002043A patent/MX2018002043A/en unknown
- 2016-08-16 RS RS20201050A patent/RS60755B1/en unknown
- 2016-08-17 AR ARP160102519A patent/AR105724A1/en unknown
- 2016-08-17 UY UY0001036859A patent/UY36859A/en active IP Right Grant
-
2018
- 2018-02-11 IL IL257468A patent/IL257468B2/en unknown
- 2018-02-15 PH PH12018500361A patent/PH12018500361A1/en unknown
- 2018-02-16 CL CL2018000431A patent/CL2018000431A1/en unknown
- 2018-02-16 MX MX2022006650A patent/MX2022006650A/en unknown
- 2018-02-16 SV SV2018005634A patent/SV2018005634A/en unknown
- 2018-02-16 CO CONC2018/0001524A patent/CO2018001524A2/en unknown
- 2018-02-16 NI NI201800027A patent/NI201800027A/en unknown
- 2018-03-14 EC ECIEPI201819568A patent/ECSP18019568A/en unknown
- 2018-03-16 ZA ZA201801789A patent/ZA201801789B/en unknown
-
2020
- 2020-08-28 HR HRP20201375TT patent/HRP20201375T1/en unknown
- 2020-08-28 CY CY20201100810T patent/CY1123297T1/en unknown
-
2021
- 2021-07-30 JP JP2021126285A patent/JP7194240B2/en active Active
-
2022
- 2022-12-08 JP JP2022196582A patent/JP2023027228A/en active Pending
-
2023
- 2023-02-22 CY CY2023007C patent/CY2023007I2/en unknown
- 2023-02-22 FR FR23C1011C patent/FR23C1011I1/en active Active
- 2023-02-22 FR FR23C1012C patent/FR23C1012I1/en active Active
- 2023-02-22 HU HUS2300011C patent/HUS2300011I1/en unknown
- 2023-02-22 NL NL301219C patent/NL301219I2/en unknown
- 2023-02-22 FI FIC20230012C patent/FIC20230012I1/en unknown
- 2023-02-23 LT LTPA2023509C patent/LTPA2023509I1/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR23C1012I1 (en) | ANTI-BCMA ANTIBODIES, BCMA AND CD3-BINDING BISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF | |
MA43164A (en) | ANTI-IL1RAP ANTIBODIES, BISPECIFIC MOLECULES OF BINDING ANTIGEN BINDING IL1RAP AND CD3 AND THEIR USES | |
MA44060A (en) | BISPECIFIC ANTI-TL1A / ANTI-TNF-ALPHA BISPECIFIC ANTIGEN PROTEINS AND THEIR USES | |
DK3411402T3 (en) | BCMA AND CD3 BISPECIFIC T-CELL INVOLVING ANTIBODY CONSTRUCTIONS | |
MA45712A (en) | ANTI-GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND TO GPRC5D AND CD3 AND THEIR USES | |
HK1255971A1 (en) | Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof | |
MA46770A (en) | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE | |
MA42935A (en) | OPTIMIZED ANTI-CD3 BISPECIFIC ANTIBODIES AND THEIR USES | |
MA44885A (en) | BISPECIFIC BINDING PROTEINS AND THEIR USES | |
EA202092435A3 (en) | MONOCLONAL ANTIBODIES AGAINST BCMA | |
MA46917A (en) | MET ANTIBODIES, MET BISPECIFIC ANTIGEN BINDING MOLECULES, AND METHODS OF USE THEREOF | |
MA42447A (en) | ANTI-PD-1 ANTIBODIES, ACTIVABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF | |
MA43308A (en) | APRIL-BOUND ANTIBODY MOLECULES AND THEIR USES | |
CY1118168T1 (en) | DOUBLE SPECIAL ANTIBODIES AGAINST CD3EXYLON AND BCMA | |
MA42808A (en) | IL-8 BINDING ANTIBODIES AND THEIR USES | |
MA43658A (en) | ANTI-MMR1 ANTIBODIES, ROR1 X CD3 BISPECIFIC ANTIBODIES, AND METHODS OF USE THEREOF | |
BR112018010360A2 (en) | anti-c1q complement factor fab fragments and uses thereof | |
MA42059A (en) | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) BISPECIFIC BINDING AGENTS AND USES | |
MA45690A (en) | ANTI-TGFB ANTIBODIES, METHODS AND USES | |
MA42821A (en) | TETRAVALENT TETRASPECIFIC AND BISPECIFIC BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF | |
MA45233A (en) | ANTI-GITR ANTIBODIES AND THEIR USES | |
MA44054A (en) | BISPECIFIC ANTIBODY PLATFORM | |
DK3247998T3 (en) | MICROFLUID PARTICLE ANALYSIS DEVICE. | |
MA43814A (en) | ANTI-GITR ANTIBODIES, METHODS AND USES | |
MA50659A (en) | BISPECIFIC ANTIGEN BINDING MOLECULES BINDING TO TARGET STAPHYLOCOCCUS ANTIGEN AND COMPONENT COMPONENT, AND THEIR USES |